Earnings Summary: Alnylam Faces Decline, Neurocrine Raises Questions, and Biogen Reports a 'Subpar' Victory

Earnings Summary: Alnylam Faces Decline, Neurocrine Raises Questions, and Biogen Reports a ‘Subpar’ Victory

Earnings Summary: Alnylam Faces Decline, Neurocrine Raises Questions, and Biogen Reports a 'Subpar' Victory